Cargando…

Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer

Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdullah, Nurul A, Inman, Martyn, Moody, Christopher J., Storr, Sarah J, Martin, Stewart G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426295/ https://www.ncbi.nlm.nih.gov/pubmed/33768386 http://dx.doi.org/10.1007/s10637-021-01106-5

Ejemplares similares

Cytotoxic and Radiosensitising Effects of a Novel Thioredoxin Reductase Inhibitor in Brain Cancers
por: Yao, Anqi, et al.
Publicado: (2022)

Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease
por: Adhikary, Sabina, et al.
Publicado: (2020)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Thioredoxin Reductase and its Inhibitors
por: Saccoccia, Fulvio, et al.
Publicado: (2014)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
por: Middleton, Fiona K., et al.
Publicado: (2018)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Enzymatic Redox Properties and Cytotoxicity of Irreversible Nitroaromatic Thioredoxin Reductase Inhibitors in Mammalian Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells
por: Márquez, Marcela, et al.
Publicado: (2022)

A novel gene expression signature for bone metastasis in breast carcinomas
por: Savci-Heijink, C. Dilara, et al.
Publicado: (2016)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer
por: Cadenas, Cristina, et al.
Publicado: (2010)

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production
por: Maria, Durvanei Augusto, et al.
Publicado: (2012)

The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines
por: Kucinska, Malgorzata, et al.
Publicado: (2018)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
por: Yan, S. Betty, et al.
Publicado: (2012)

Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients
por: Mast, Mirjam E., et al.
Publicado: (2014)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Improving breast cancer services for African-American women living in St. Louis
por: Noel, Lailea, et al.
Publicado: (2015)

A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
por: Verdone, Christopher G., et al.
Publicado: (2022)

The importance of early detection of calcifications associated with breast cancer in screening
por: Mordang, J. J., et al.
Publicado: (2017)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Retrospective analysis of metastatic behaviour of breast cancer subtypes
por: Savci-Heijink, C. Dilara, et al.
Publicado: (2015)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2022)

Promoter hypermethylation profiling of distant breast cancer metastases
por: Schrijver, Willemijne A. M. E., et al.
Publicado: (2015)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm
por: Lu, Yuanyuan, et al.
Publicado: (2019)

Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
por: Kusaczuk, Magdalena, et al.
Publicado: (2016)

MUTYH gene variants and breast cancer in a Dutch case–control study
por: Out, Astrid A., et al.
Publicado: (2012)

Association of reproductive history with breast tissue characteristics and receptor status in the normal breast
por: Gabrielson, Marike, et al.
Publicado: (2018)

Engineering targeted chromosomal amplifications in human breast epithelial cells
por: Springer, Simeon, et al.
Publicado: (2015)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

Current practice and provision of oncoplastic breast-conserving surgery in the UK: results of the ANTHEM national practice questionnaire
por: Davies, Charlotte, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8m21298d3h57444li79qs2okhl